Abstract：【Objective】 To observe the curative effect and safety of the first dose loading and the repeated loading dose of ibandronate in the treatment of metastatic bone pain of malignant tumors. 【Methods】 Forty patients with malignant bone metastases from 2012 to 2017 were selected, including 20 cases in the first dose loading group (group A) and 20 cases in the repetitive loading dose group (group B). The pain score, quality of life KPS score, onset time of analgesia, duration of analgesia maintenance, and adverse reactions were observed and recorded before and after the application of ibandronate. 【Results】 The effective rate of pain relief was 55% (11/20) in the group A and 90% (18/20) in the group B (P<0.05). The scores of quality of life (QOL) in the group A (83±10.89) were lower than those in the group B (91.00±7.88), and the difference was significant (P<0.05). The time of analgesic effect and maintenance were (3.60 ±0.50) days and (20.35 ±1.87) days in the group A, lower than those in the group B (2.70±0.40) days and (23.30±1.34) days, respectively (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).【Conclusion】 Repeated administration of ibandronate has a good analgesic effect and could improve metastatic bony pain rapidly, the kidney of the patients has good tolerance and mild adverse reaction, which is worth popularizing.
杨露露, 邓文英, 罗素霞. 伊班膦酸钠治疗恶性肿瘤骨转移痛的临床疗效[J]. 医学临床研究, 2018, 35(8): 1461-1463.
YANGLu-lu, DENGWeng-ying, LUOSu-xia. The Clinical Study of Ibandronate Administration in the Treatment of Metastatic Bone Pain in the Patients of Malignant Cancer. JOURNAL OF CLINICAL RESEARCH, 2018, 35(8): 1461-1463.
[1] 董梅,冯奉仪.双膦酸盐治疗恶性肿瘤骨转移的基础研究与临床实践[J].癌症进展志,2006,14(14):366-369. [2] Michael G, Philippe C. Direct and indirect anticancer activity of bisphosphonate: A brief review of published literature[J].Cancer Treatment Reviews,2012,38(5):407-415. [3] Bhandari V, Jain RK. A retrospective study of incidence of bone metastasis in head and neck cancer[J].J Cancer Res Ther,2013,9(1):90-93. [4] 姚强,华东,魏巍.伊班膦酸钠对人肺癌细胞株A549生长及其对VEGF表达的影响[J].现代肿瘤医学,2009,17(4),645-647. [5] Heras P, Kritikos k, Hatzopoulos A,et al.Efficacy of ibandronate for the treatment of skeletal events in the patient with metastatic breast cancer[J].Eur J Cancer,2009,18(6):653-656. [6] Mancini I, Dumon J. Efficacy and safety of ibandronate in the treatment of opiod-resistant bone pain associated with metastatic bone disease: A pilot study [J].J Clin Oncol,2004,22(17):3587-3590. [7] 关素梅,张勇.负荷剂量伊班膦酸钠治疗肺癌骨转移的临床观察[J].中国药房,2011,22(4):338-339. [8] Kadri A, Omer D, Zeynep O,et al.Phase 2 study of loading-Dose ibandronate treatment in patient with breast cancer and bone metastases suffering from moderate to severe pain[J].Onkologie,2012,35(5):254-285.
2018, Vol. 35 
